This paper is only available as a PDF. To read, Please Download here.
Abstract
The hormonal milieu at the time of surgery may influence mortality and disease-free
survival in patients with primary breast cancer. Indeed, there is evidence that circulating
unopposed estrogen is detrimental and that the presence of circulating progesterone
results in an improved disease-free and overall survival rate. Thus patients who receive
neoadjuvant progesterone therapy may have a better outcome. A randomized controlled
trial in which women with primary breast cancer receive either progesterone or placebo
before surgery is urgently needed to confirm this hypothesis.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Timing of surgery during the menstrual cycle and survival of premenopausal women with operable breast cancer.Lancet. 1991; 337: 1261-1264
- Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival.Ann Intern Med. 1991; 115: 337-342
- Effect of menstrual phase on surgical treatment of breast cancer.Lancet. 1994; 343: 1545-1547
- Observation on Indian node-negative breast cancer patients: A multivariate analysis.J Surg Oncol. 1989; 42: 256-263
- Breast cancer in 3558 women: Age as a significant prognostic determinant in the rate of dying and causes of death.Surgery. 1978; 83: 123-132
- Body weight and prognosis in breast cancer.J Natl Cancer Inst. 1981; 67: 785-789
- Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway.Int J Cancer. 1989; 44: 23-30
- Prospective look at breast surgery timing.Lancet. 1994; 344 (Commentary): 1013
- Menstrual timing of breast cancer resection: Prospective trial is overdue.J Natl Cancer Inst. 1995; 87: 143-144
- Menstrual influence on surgical cure of breast cancer.Lancet. 1989; 2: 949-952
- Menstrual surgical timing.Lancet. 1991; 337 (Letter): 1604
- Optimal mastectomy timing.J Natl Cancer Inst. 1992; 84: 346-348
- Effect of menstrual phase on surgical treatment of breast cancer.Lancet. 1994; 344: 402-403
- Timing of surgery during the menstrual cycle for operable breast cancer.Cancer Top. 1993; 9: 42-43
- Serum progesterone at time of surgery and survival in women with premenopausal operable breast cancer.Eur J Cancer. 1994; 30A: 445-448
- Source of estrogen production in post-menopausal women.J Clin Endocrinol Metab. 1973; 36: 207-214
- The hormonal milieu and prognosis in operable breast cancer.Cancer Surv. 1993; 18: 149-163
- Influence of menopause on bone marrow micrometastases in early breast cancer. Abstract. book 1.Sixteenth International Cancer Congress, New Delhi, India. 1994; : 160
- Effect of surgical removal on the growth and kinetics of residual tumor.Cancer Res. 1979; 39: 3861-3865
- Presence of a growth-stimulating factor in serum following primary tumor removal in mice.Cancer Res. 1989; 49: 1996-2001
- Progress from clinical trials on breast cancer.Cancer. 1994; 74: 2606-2609
Article info
Footnotes
☆The opinions or assertions contained herein are the private views of the author and are not to be construed as reflecting the views of the Departments of the Army, Air Force, or Defense.
Identification
Copyright
© 1997 Published by Elsevier Inc.
